Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC) (Q80215475)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 April 2007

Language	Label	Description	Also known as
English	Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)	scientific article published on 26 April 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

prostate cancer

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

8

object named as

Eric J Small

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Charles J Ryan

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Walter M Stadler

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Bruce Roth

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Douglass Hutcheon

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Shauna Conry

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Thomas Puchalski

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Charles Morris

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

26 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

445-451

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17458505%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

https://scigraph.springernature.com/pub.10.1007/s10637-007-9050-y

0 references

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis and prostate cancer: identification of a molecular progression switch

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological factors influencing anticancer drug selection in the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17458505

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80215475&oldid=2186406946"